Abstract: ［Abstract］ Objective〖HTSS〗To observe the effect of Lilalutide on insulin resistance and visceral fat in type 2 diabetes mellitus (T2DM) patients treated by insulin combined with metformin with poor glycemic control. 
〖WTHZ〗Methods〖HTSS〗Eighty cases of overweight and obese T2DM patients were screened, and the glycated hemoglobin(HbA1c) was consistent with that of 7%≤HbA1c≤ 11%. They were randomly divided into two groups, the insulin combined with metformin group(control group) and the insulin combined with metformin group with Liraglutide(Liraglutide group), and the treatment was conducted for 24 weeks. Body weight(WT) before and after treatment, waist circumference,(WC), body mass index(BMI), fasting blood sugar(FPG), total cholesterol(TC), three triglyceride(TG), low density lipoprotein cholesterol(LDL-C), high density lipoprotein cholesterol(HDL-C), HbA1c, fasting insulin( FINS), insulin resistance index(HOMA-IR) and visceral fat area(VFA) changes were observed.
〖WTHZ〗Results〖HTSS〗After treatment, FPG, TC, TG, HbA1c, LDL -C,FINS, HOMA -IR in the control group were all reduced and HDL-C was increased, with statistically significant differences(P＜0.05). WT, WC, BMI, FPG, HbA1c, TC, TG, FINS, HOMA-IR and VFA were all reduced and HDL-C was increased in the Liraglutide group compared with that before treatment, the difference was statistically significant(P＜0.05).After treatment, WT, WC, BMI and VFA in Liraglutide group were all lower than those in the control group(P＜0.05). Compared with the control group, the daily insulin dose of Liraglutide group decreased(P＜0.05). Decreased VFA was positively correlated with decreased WT, WC and BMI(P＜0.05).
〖WTHZ〗Conclusion〖HTSS〗The application of Liraglutide in overweight and obese patients with type 2 diabetes can not only lower blood sugar but also reduce weight, improve insulin resistance and reduce visceral fat, with clinical benefits.

Key words: diabetes mellitus,  , type 2； obesity； visceral fat